Investing In CBD Stocks Offers Opportunity But Risks
In the News: Shared from Forbes
Cannabidiol (CBD) has taken off lately, and the recent passage of the Farm Act in December has accelerated interest in the cannabinoid found in cannabis plants that was also the active ingredient in the first FDA approved drug derived from botanical cannabis, GW Pharmaceuticals’s Epidiolex, which is indicated for the treatment of seizures in treatment-resistant forms of two types of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Products containing CBD are becoming increasingly available in a variety of formats and through an increasing number of venues, with consumers able to access products derived from industrial hemp through mail order, convenience stores, health food stores, some restaurants and coffee shops and now even malls. CBD is also sold through state-regulated medical cannabis programs or in states where cannabis is legal for adult-use and can be derived from plants that fall outside the definition of industrial hemp, with THC levels above 0.3% of the weight.
The mainstreaming of CBD began years ago, with the 2013 CNN Special ‘Weed’, hosted by Dr. Sanjay Gupta, bringing attention to the potential health benefits of CBD to a global audience. Despite a murky regulatory environment, several companies…